Colorectal Cancer Clinical Trials in Boston, Massachusetts

32 studies are recruiting for colorectal cancer in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

   High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of high…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Boston Medical Center, Boston, Massachusetts

   Locations

   45 in total

   Run by

   Takeda

   See if you can join NCT06562543 on ClinicalTrials.gov

2. A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

   The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal can…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana-Farber/Massachusetts General Hospital, Inc, Boston, Massachusetts

   Locations

   9 in total

   Run by

   PAQ Therapeutics, Inc.

   See if you can join NCT07300150 on ClinicalTrials.gov

3. COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

   This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemotherapy and radiotherapy) for stage I-III colorectal cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT05692024 on ClinicalTrials.gov

4. Remote Monitoring and Symptom Management Digital Application

   The goal of this clinical trial is to learn if an artificial intelligence phone application called ASSIST can help patients receiving cancer treatment. The main question[s] it aims to answer are: Is ASSIST feasible for patients (meaning can it be used by patients)? Is ASSIST acceptable to patients …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Patrick C. Johnson, MD

   See if you can join NCT07553572 on ClinicalTrials.gov

5. This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

   This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Zumutor Biologics Inc.

   See if you can join NCT06451497 on ClinicalTrials.gov

6. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

   This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   14 in total

   Run by

   858 Therapeutics, Inc.

   See if you can join NCT06395519 on ClinicalTrials.gov

7. Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

   The overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Lumicell, Inc.

   See if you can join NCT02584244 on ClinicalTrials.gov